No Data
No Data
Schrödinger To Present Phase 1 Clinical Data On MALT1 Inhibitor SGR-1505 At EHA Annual Congress And International Conference On Malignant Lymphoma
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Trulieve Cannabis (OtherTCNNF) and Schrodinger (SDGR)
BofA Securities Maintains Schrodinger(SDGR.US) With Hold Rating, Announces Target Price $26
TD Cowen Maintains Schrodinger(SDGR.US) With Buy Rating, Maintains Target Price $33
Craig-Hallum Maintains Schrodinger(SDGR.US) With Buy Rating, Announces Target Price $30
Analysts' Opinions Are Mixed on These Healthcare Stocks: Veracyte (VCYT), Schrodinger (SDGR) and Korro Bio (KRRO)